Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.

ABSTRACT:

Background

Systemic inflammation and immune dysregulation are recognized as key determinants of cancer progression and survival. The pan-immune-inflammation value (PIV), a hematologic-based composite biomarker, may reflect the host's immune-inflammatory status. Its prognostic significance in brain metastases (BM), however, remains undefined.

Methods

In a single-center retrospective cohort, 3,856 consecutive patients with radiologically confirmed BM diagnosed between 2013 and 2021 were included. PIV was calculated as neutrophil count × platelet count × monocyte count, divided by lymphocyte count. All blood cell counts were recorded in units of 10^9 cells per liter. Complete blood counts were taken within 7 days before the start of treatment. The optimal PIV cut-off, derived u

SUBMITTER: Li J 

PROVIDER: S-EPMC12815847 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature